Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients.

ABSTRACT:

Introduction

There is a critical need of new surrogate markers for improving the therapeutic selection and monitoring of metastatic prostate cancer patients. Nowadays clinical management of these patients is been driven by biochemical and clinical parameters without enough accuracy to allow a real personalized medicine. The present study was conducted to go insight the molecular profile of circulating tumor cells (CTCs) isolated from advanced metastatic castration-resistant prostate cancer (mCRPC) with the aim of identifying prognostic marker with potential utility for therapy selection and monitoring.

Materials and methods

CTCs isolation was carried out in peripheral blood samples from 29 mCRPC patients that undergo systemic chemotherapy based on taxanes (docetaxel/cabazita

SUBMITTER: Leon-Mateos L 

PROVIDER: S-EPMC5589615 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature